ArticleJournal of clinical practice and research2025
A Comparison of Short and Long-Term Acting Dopamine Agonists in the Treatment of Parkinson's Disease with Respect to the Side Effects of Impulse Control Disorder.
Article in Journal of clinical practice and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Impulse control disorders are thought to emerge as a result of the pulsatile stimulation of dopamine D3 receptors in the limbic-ventral striatum with dopamine treatment. According to this pathophysiology, it is argued that the use of long-acting dopamine agonists leads to fewer impulse control disorders than the use of short-acting dopamine agonists. This study aimed to compare short and long-acting dopamine agonists with respect to impulse control disorders in patients with Parkinson's disease. Materials and Methods: Seventy-five patients with Parkinson's disease were examined with respect to impulse control disorders. All the patients were administered the Barratt Impulsivity Scale Short Form to determine impulsivity and the Movement Disorder Society- Unified Parkinson's Disease Rating Scale to evaluate disease severity. Results: There was no significant difference between the patient groups using short and long-acting dopamine agonists for impulsivity (p=0.966, p=0.052, respectively). The Barratt Impulsivity Scale scores were seen to be higher in the patients who were illiterate compared to the other educational level groups (p<0.001), and there was no significant difference in respect of other demographic data (p>0.05). Male gender (odds ratio [OR]: 4.000, 95% CI: 1.164-13.745, p=0.028) and a high score on the Movement Disorder Society- Unified Parkinson's Disease Rating Scale (OR: 3.636, 95% CI: 1.394-9.484, p=0.008) were found to be associated with impulse control disorders. Conclusion: The results of this study showed no difference between short and long-acting dopamine agonists with respect to the development of impulse control disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.